NTI164 Reverses Immune Dysregulation in PANDAS/PANS Children
Filed with ASX · · 4 pages · English
Neurotech International Ltd. on 6ix
Earlier from Neurotech International
- Neurotech Global Partnering and Registration Strategy
- Further Significant Improvement in Rett Syndrome Patients
- Phase II/III autism trial shows further benefits
- Significant improvement in Autism patients at 12 weeks
- Phase I/II Autism Patients Meet 2 Years of NTI164 Treatment
Later from Neurotech International
- US FDA Response to Orphan Drug Request in PANDAS/PANS
- Neurotech Appoints Dr Anthony Filippis as MD/CEO
- Positive Genomic Effects of NTI164 in PANDAS/PANS Patients
- NTI Receives Ethics Approval to Commence Human PK Study
- Neurotech Receives US ODD in Rett Syndrome
Follow Neurotech International into a list and get an email when it puts out news.
Follow Neurotech International